Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2018 | Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma

Nathan Fowler • 1 Jun 2018
ASCO 2018
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide Rituximab
RELEVANCE

Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Nathan Fowler, MD, of the MD Anderson Cancer Center, Houston, TX, discusses these results and their importance here.

More from Nathan Fowler

ELARA: Tisa-cel in follicular lymphoma
1:36
ELARA: Tisa-cel in follicular lymphoma
Nathan Fowler • 12 Dec 2021
10 year follow up of rituximab and lenalidomide in low tumor burden FL
0:39
10 year follow up of rituximab and lenalidomide in low tumor burden FL
Nathan Fowler • 12 Dec 2021
RELEVANCE: Rituximab and lenalidomide in FL
1:03
RELEVANCE: Rituximab and lenalidomide in FL
Nathan Fowler • 12 Dec 2021
ELARA: tisa-cel in R/R follicular lymphoma
3:44
ELARA: tisa-cel in R/R follicular lymphoma
Nathan Fowler • 18 Jun 2021

Related Videos

Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
2:24
Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
Nathan Fowler • 10 Dec 2025
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
1:13
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
Nathan Fowler • 10 Dec 2025
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
5:31
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Nathan Fowler • 10 Dec 2025
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Nathan Fowler • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals